The Food and Drug Administration has revealed that the maker of a brand of eye drops linked to an outbreak of fatal bacterial infections failed to follow multiple safety protocols.
The FDA visited a Global Pharma Healthcare facility in India for an inspection in mid-February and found dozens of issues ranging from dirty equipment and clothing to missing safeguards and procedures.
The inspection came two-and-a-half weeks after the company voluntarily recalled the EzriCare artificial tears product because of possible contamination.
When the recall was issued, there were already 55 reports of adverse events, including eye infections, permanent loss of vision, and at least one death from a bloodstream infection.
Even with inflation slightly higher than the Federal Reserve's 2% goal, still expect the central bank to cut rates three times this year, Cetera's CIO says.
Brian Goodman from Global Matrix Group talks with Dave Briggs about the future of sports betting online and how the popular pastime will evolve. Watch!
For decades, it’s been a trope: you can find a Starbucks on every corner. But proximity is no guarantee of long-term success, even in the coffee industry.
Tesla is being investigated for allegedly misleading investors about its self-driving capabilities. And one analyst says the company 'needs' that tech to grow.
